Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Ability to understand and sign a written informed consent documen；
At the date of signing ICF, 18 ~70 years old, male or female；
Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
Positive mesothelin expression;
None
Single group
CHT102
DrugCHT 102 : MSLN UCAR-T.
Safety and Tolerability
Treatment-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Objective response rate (ORR)
The total response rate after 90 days of treatment with study drug.
Disease control rate (DCR)
The disease control rate after 90 days of treatment with study drug.
Progress-free survival(PFS)
PFS will be assessed from the first CHT102 infusion to death from any cause or the first assessment of progression (Assessed based on RECIST criteria)
Overall survival (OS )
OS will be assessed from the first CHT102 infusion to death from any cause (Assessed based on RECIST criteria)
Click on the lead sponsor to view all of their trials.
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Collaborator
